These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29969922)

  • 1. Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs.
    Skubic C; Drakulić Ž; Rozman D
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):831-841. PubMed ID: 29969922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.
    Ballestri S; Nascimbeni F; Baldelli E; Marrazzo A; Romagnoli D; Lonardo A
    Adv Ther; 2017 Jun; 34(6):1291-1326. PubMed ID: 28526997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.
    Lorbek G; Urlep Ž; Rozman D
    Pharmacogenomics; 2016 Jul; 17(11):1273-1288. PubMed ID: 27377717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    Seto WK; Yuen MF
    J Gastroenterol; 2017 Feb; 52(2):164-174. PubMed ID: 27637587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview.
    Marchisello S; Di Pino A; Scicali R; Urbano F; Piro S; Purrello F; Rabuazzo AM
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Burra P; Bizzaro D; Gonta A; Shalaby S; Gambato M; Morelli MC; Trapani S; Floreani A; Marra F; Brunetto MR; Taliani G; Villa E;
    Liver Int; 2021 Aug; 41(8):1713-1733. PubMed ID: 33982400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease.
    Cespiati A; Youngson NA; Tourna A; Valenti L
    Curr Pharm Des; 2020; 26(10):998-1009. PubMed ID: 31969087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
    Cernea S; Cahn A; Raz I
    Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes.
    Nascimbeni F; Pellegrini E; Lugari S; Mondelli A; Bursi S; Onfiani G; Carubbi F; Lonardo A
    Atherosclerosis; 2019 May; 284():66-74. PubMed ID: 30875495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.
    Lonardo A; Nascimbeni F; Ballestri S; Fairweather D; Win S; Than TA; Abdelmalek MF; Suzuki A
    Hepatology; 2019 Oct; 70(4):1457-1469. PubMed ID: 30924946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.
    Sayiner M; Koenig A; Henry L; Younossi ZM
    Clin Liver Dis; 2016 May; 20(2):205-14. PubMed ID: 27063264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonobese Fatty Liver Disease.
    Kim D; Kim WR
    Clin Gastroenterol Hepatol; 2017 Apr; 15(4):474-485. PubMed ID: 27581063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.